FDA Grants Bluebird BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
TheFDAhasgrantedBluebirdbb2121abreakthroughtherapydesignationforpreviouslytreatedpatientswithrelapsed/refractorymultiplemyeloma,accordingtoCelgeneCorporationandbluebirdbio,thecompaniesdevelopingtheant